Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
about
Vedolizumab for the treatment of ulcerative colitis and Crohn's diseaseStratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupNatalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent RegistryThe safety of vedolizumab for the treatment of ulcerative colitis.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Adverse events in IBD: to stop or continue immune suppressant and biologic treatmentRapidly progressive cerebellar ataxia in West WalesTreatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon βMultiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.Natalizumab therapy for multiple sclerosisNatalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.Targeting integrins and adhesion molecules to combat inflammatory bowel disease.Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches.Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.Infection risk with biologic therapy in patients with inflammatory bowel disease.Progressive multifocal leukoencephalopathy after natalizumab discontinuation.What is the role of vedolizumab in the era of anti-TNF agents?Body weight-based natalizumab treatment in adult patients with multiple sclerosis.To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.The still under-investigated role of cognitive deficits in PML diagnosis
P2860
Q24630083-F7C72D8D-DF83-4AB6-9797-A9E09B110885Q26780412-B39E3DEA-CE07-4F32-B5BE-6B9C008637EBQ28555138-02A71861-C196-4C43-ACAE-BC43038819BDQ30235363-B46B661E-6BB1-44B7-B40D-B46A92BAF962Q33755345-3C01C381-53EA-4C3A-8C61-8AB3C5B38522Q34073191-03A329A9-166B-4675-9BBD-740317A91A6EQ35050193-80C4154A-5299-4051-A4F8-7863DFAE1DB1Q35103997-BA032916-D797-40B1-8E7D-F58C332A65C4Q36290143-C162241D-6F4C-46A7-B180-DC8B801F8803Q36568666-A5C18C49-78E2-4CDC-A963-1D9C36A830ABQ38167347-7CDEC982-922E-412C-813B-CE55316A0A5EQ38248635-FEB7CEF5-7211-4842-B2C6-EBCFDF1642B9Q38542151-493BE178-67CC-4FED-93F4-1DE78F9FBFF0Q38715286-9680A925-9EB6-4E88-A440-6D5E6AF0C70AQ38801394-E7158B14-2BF4-4C6E-A598-79761C63E37AQ38812688-9E992343-EFBB-4718-87EF-4305E1390056Q39211049-212701D4-241D-4937-AAA7-F2E4E2E15E59Q39429997-6517C6C3-25EE-4B92-8A23-211454325598Q42255115-F402D1C1-05C0-461A-9BEA-16A19EB3C97EQ42948666-1C6F7E6B-2DE7-49E2-92DD-5AC1F2F41AD3Q47406798-D41E5CB3-5627-4603-AE00-47610FFC3885Q47812653-2DA18268-BFC8-45A2-B324-2474A2E21B31Q58864832-18C7B31E-CE93-4909-9A8E-84DFFDCA0B75
P2860
Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Natalizumab-associated progres ...... risk profiling and monitoring
@ast
Natalizumab-associated progres ...... risk profiling and monitoring
@en
Natalizumab-associated progres ...... risk profiling and monitoring
@en-gb
Natalizumab-associated progres ...... risk profiling and monitoring
@nl
type
label
Natalizumab-associated progres ...... risk profiling and monitoring
@ast
Natalizumab-associated progres ...... risk profiling and monitoring
@en
Natalizumab-associated progres ...... risk profiling and monitoring
@en-gb
Natalizumab-associated progres ...... risk profiling and monitoring
@nl
prefLabel
Natalizumab-associated progres ...... risk profiling and monitoring
@ast
Natalizumab-associated progres ...... risk profiling and monitoring
@en
Natalizumab-associated progres ...... risk profiling and monitoring
@en-gb
Natalizumab-associated progres ...... risk profiling and monitoring
@nl
P2093
P1433
P1476
Natalizumab-associated progres ...... risk profiling and monitoring
@en
P2093
C. Hawkins
G. Giovannoni
G. Mazibrada
P356
10.1136/PRACTNEUROL-2011-000092
P407
P577
2012-01-18T00:00:00Z